CDC panel recommends U.S. resume use of J&J Covid vaccine, saying benefits outweigh risks

A Centers for Disease Control and Prevention advisory panel on Friday recommended the U.S. resume using the Johnson and Johnson Covid-19 vaccine, saying the benefits outweighed the risk.

Members of the panel didn’t recommend U.S. regulators restrict the use of the vaccine based on age or gender, but they did propose that the FDA consider adding a warning label for women under the age 50.

The recommendation, which was adopted 10-4 with one abstention, by the CDC’s Advisory Committee on Immunization Practices, will pave the way for U.S. regulators to lift their recommended pause on using the J&J shot as early as this weekend.